[Translation] A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in subjects with Parkinson's disease
主要目的: 评估BIIB122 225 mg与安慰剂相比的有效性
次要目的: 评估BIIB122 225 mg与安慰剂相比的安全性和耐受性 评估BIIB122 225 mg与安慰剂相比的有效性
药代动力学: 表征BIIB122在血浆和CSF中的PK特征
[Translation] Primary objective: To assess the effectiveness of BIIB122 225 mg compared to placebo
Secondary objectives: To assess the safety and tolerability of BIIB122 225 mg compared to placebo To assess the efficacy of BIIB122 225 mg compared to placebo
Pharmacokinetics: Characterization of the PK profile of BIIB122 in plasma and CSF